Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases

Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) – the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.<br><br>

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases. <br> Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis. <br><br> Besides their use in inflammatory lung diseases the novel bisphosphonates with prolonged carbon chain may be used as treatment option for cystic fibrosis and atherosclerosis.<br><br> <b>Benefits:</b><br> <ul> <li>Neutral sphingomyelinase is not influenced</li> <li>First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent</li> <li>Inhibition of dexamethasone induced apoptosis was proven <em>in vitro</em></li> <li>Substances can easily be synthesized in a one-step or two-step procedure</li> <li>Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate</li> </ul> <p><strong>IP Rights</strong><br> EP Application (08/2009).<br> PCT Application (08/2010). <br> A PCT application was filed in August 2010.<br> <br> <strong>Patent Owner</strong><br> Humboldt-Universität zu Berlin<br> Rheinisch-Westfälische<br> Technische Hochschule Aachen (RWTH)<br><br> <b>Find the technology offer and contact details here: <a href=“http://www.ipal.de/technologieangebote/09061″ target=“_blank“>http://www.ipal.de/technologieangebote/09061</a></b>

Weitere Informationen: PDF

ipal GmbH
Tel.: +49 (0)30/2125-4820

Ansprechpartner
Dr. Dirk Dantz